Mass Spec

News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.

Jun 2, 2022

InterVenn BioSciences Hits Commercial Phase, Launches Test for Immunotherapy Response in Melanoma
Premium

Jun 2, 2022

InfanDx Eyes 2023 Launch for Hypoxic-Ischemic Encephalopathy IVD; POC Test Also Planned
Premium

Jun 1, 2022

BioMérieux Invests €2M in French Sepsis Dx Startup Weezion

May 31, 2022

BCAL Looks to Commercialize Breast Cancer Lipid Assay in US, Beyond
Premium

May 4, 2022

First FDA EUA for Breath-Based COVID Test in Hand, InspectIR Focusing on Commercialization
Premium

Apr 14, 2022

Researchers Develop Lipidomics Approach to Predict Cardiovascular Disease, Diabetes
Premium

Apr 7, 2022

MALDI Clinical Microbiology Releases Bring New Features, Could Open Additional US Markets
Premium

Mar 18, 2022

BioMérieux Gets FDA 510(k) Clearance for MALDI-TOF Bacterial ID System

Feb 11, 2022

Machine Learning May Extend MALDI Mass Spec-Based Antibiotic Resistance Testing
Premium

Feb 2, 2022

Blood Lipid Mass Spectrometry Assay May Enable Early-Stage Lung Cancer Detection

Jan 24, 2022

Fluidigm Obtains $250M Investment, Changing Name to Standard BioTools

Jan 6, 2022

Virtue Diagnostics Raises $100M in Series B Financing

Jan 6, 2022

Copan Diagnostics Receives FDA 510(k) Clearance for Colibri Clinical Microbiology System

Dec 15, 2021

Elypta Expands Trial for Liquid Biopsy Kidney Cancer Recurrence Test; Plans Bladder Cancer Assay
Premium

Nov 16, 2021

BioMark Diagnostics Nabs Canadian Funding for Lung Cancer Liquid Biopsy

Nov 9, 2021

Sera Prognostics Revenues, Net Loss Up in Q3

Aug 31, 2021

Sera Prognostics' Revenues, Loss Tick up in Q2

Aug 26, 2021

Stanford Team Developing Metabolomic Technique to Detect Influzenza, Other Respiratory Viruses
Premium

Aug 4, 2021

InterVenn Biosciences Using New Funding to Develop Glycoproteomic Immunotherapy Response Assay
Premium

Aug 2, 2021

InterVenn Biosciences Closes $201M Series C Round